Commentary on opinion pieces re Australian human papillomavirus vaccine policy
Peter McIntyre
+ Author Affiliations
- Author Affiliations
The National Centre for Immunisation Research, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. Email: peterm@chw.edu.au
Sexual Health 7(3) 242-243 https://doi.org/10.1071/SH10026
Submitted: 1 March 2010 Accepted: 21 May 2010 Published: 19 August 2010
References
[1] Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185 251–7.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[2] Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs – do vaccines warrant a different approach? Lancet Infect Dis 2008; 8 727–33.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3] Brotherton J, Deeks S, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32 457–61.
| PubMed |
[4] Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85 499–502.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[5] Stern PL. For debate: that Australia should consider changing to the bivalent vaccine. Sex Health 2010; 7 238–41.
| Crossref | GoogleScholarGoogle Scholar |
[6] Wain G. For debate: that Australia should continue using the quadrivalent vaccine. Sex Health 2010; 7 235–7.
| Crossref | GoogleScholarGoogle Scholar |
[7] Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006; 91 689–91.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[8] Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 a769.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[9] de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101 1083–92.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[10] Eggerston L. Two provinces to study two doses of HPV vaccine. Can Med Assoc J 2007; 177 445–6.
| Crossref | GoogleScholarGoogle Scholar |
